We held our EU-IPFF Annual General Meeting on 15-16 July 2022. At the meeting I was elected President of EU-IPFF for a second term of two years. I am delighted to be able to continue working with my amazing colleagues at EU-IPFF. In just six years, EU-IPFF has become firmly established as the voice of Pulmonary Fibrosis Patients across Europe. Over this time, we have had many successes and have become recognised by official bodies across the continent. Most recently, I am pleased to report, we have become an eligible organisation of the European Medicines Agency (EMA), which means we can now nominate representatives to take part in EMA's scientific assessments, for example for new pulmonary fibrosis drugs and other treatments Also, at the AGM, we agreed to change our name to the European Pulmonary Fibrosis Foundation. This change recognises our focus on patients living with all types of pulmonary fibrosis, not just IPF. The abbreviation will be the same "EU-IPFF" but with "European Pulmonary Fibrosis Foundation" as the tagline in the logo. There is so much to do to tackle the challenges facing the pulmonary fibrosis community. In our 2023 -2025 strategy, we outline our future priorities. This was completed while implementing our 2022 work programme, which includes the annual Awareness Month Campaign in September, the second EU-IPFF Pulmonary Fibrosis Patient Summit in November and our webinar series. Additionally, the Board is busy working on advisory boards, committees and other activities to strengthen the patient voice in industry and among the researcher community Despite the situation in Europe, with health care systems struggling due to COVID and under financial stress, we remain dedicated to creating awareness about pulmonary fibrosis, promoting research and development towards finding a cure for this dreadful disease, improving the treatment received by patients and improving access to lung transplantation for people living with pulmonary fibrosis. We wish you a nice summer. Steve Jones |